SecBot SecBot

KURA

Kura Oncology, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001422143 Biotech & Drug Discovery
$7.09 −0.68 (−8.75%)
Nov 16 4:00 PM ET · prev $7.77
Market cap
$682.7M
Small cap
Consensus
Buy
91% Buy or better · 22 analysts
Median target
$28.00
+295% · range $15.00–76.00
1 year
−34.7%
from $10.85 · Nov 17
30 days
−24.3%
from $9.36
52-week range
$6.80–13.59
−48% from high · low Nov 5
Avg volume 20D
2.39M
Nov 4 spike 8.21M
Short interest
12.64M
≈14.2% of shares · −11.7%
Days to cover
7.9
at average volume
Insider net
−$343.0K
12 mo · excl. 2 subscriber-only trades
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
20
analyzed by SecBot
SecBot read BULLISH 12 reports · 90 days
Balance 1 bearish · 5 bullish · 6 neutral oldest → newest, height = score
Avg score ·High conf. 6/12

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersMIXED

    1 insider bought $2.4M. 6 insiders sold $2.7M. Excludes 2 subscriber-only trades.

  • InstitutionsBULLISH

    Q3 2026: 25 added (0 new), 14 trimmed or exited.

  • AnalystsBULLISH

    20 of 22 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.892 → −$0.811 over 90 days.

  • Short sellersSTEADY

    Short interest −11.7% to 12.64M shares. 7.9 days to cover, ≈14.2% of shares.

  • TrendDOWNTREND

    29% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
ARROWSTREET CAPITAL, LIMITED PARTNERSHIPADD2,751,191$29.5M
Qube Research & Technologies LtdADD1,848,485$19.8M
JUPITER ASSET MANAGEMENT LTDDOUBLED1,468,499$15.7M
HRT FINANCIAL LPDOUBLED1,196,624$12.8M
DIMENSIONAL FUND ADVISORS LPTRIM681,316$7.3M
FMR LLCADD641,620$6.9M
Jump Financial, LLCTRIM372,409$4.0M
FRANKLIN TEMPLETON INCDOUBLED335,127$2.6M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

22 analysts
Buy 91% rate it Buy or better
Strong Buy6Buy14Hold2Sell0Strong Sell0
12-month targets · 13 analysts

Price is below the lowest target. Median implies +295%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Oct 1, 2026JP Morgan
INITIATE
INITIATEOverweight
Aug 24, 2026Citizens
REITERATE
REITERATEMarket Outperform
Aug 13, 2026Wedbush
MAINTAIN
MAINTAINOutperform
Jul 28, 2026Wedbush
REITERATE
REITERATEOutperform
Jun 15, 2026Citizens
REITERATE
REITERATEMarket Outperform

Insider ledger

Form 4
$2.4M
bought · 1 insider
$2.7M
sold · 6 insiders · excl. 2 subscriber-only trades
DateInsiderTypeValue
Nov 16, 2026🔒 Fresh data, subscribers only
Nov 16, 2026
BUY
Nov 13, 2026🔒 Fresh data, subscribers only
Nov 13, 2026
BUY
Sep 29, 2026
FORD KATHLEEN
Chief Operating Officer
Sep 29, 2026
SELL$39.4K
Sep 29, 2026
Leoni Mollie
Chief Medical Officer
Sep 29, 2026
SELL$309.6K
Sep 29, 2026
Powl Brian T.
Chief Commercial Officer
Sep 29, 2026
SELL$165.9K
Sep 28, 2026
FORD KATHLEEN
Chief Operating Officer
Sep 28, 2026
SELL$72.5K
Sep 28, 2026
Leoni Mollie
Chief Medical Officer
Sep 28, 2026
SELL$130.7K
Sep 28, 2026
DOYLE THOMAS JAMES
SVP, Finance & Accounting
Sep 28, 2026
SELL$48.4K

Earnings setup

Estimates
−$0.81
EPS estimate, this quarter
+9%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.81-$0.99–-$0.69-0.6%$31.7M
Next Q-$0.69-$0.80–-$0.60-1.5%$39.4M
Current FY-$3.21-$3.45–-$3.07-1.2%$94.0M
Next FY-$2.39-$3.31–-$1.75-1.7%$200.4M

Short side

FINRA· Oct 30, 2026
12,640,858
shares short
-11.7%
vs prior settlement
7.9
days to cover
≈14.2%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 Insider
🔒 Fresh data, subscribers only
Nov 13, 2026 Other
Kura Oncology to Participate in Two Investor Conferences in November
SAN DIEGO, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical
Nov 13, 2026 Insider
🔒 Fresh data, subscribers only
Nov 4, 2026 Press
Kura Oncology and Kyowa Kirin announced that eight abstracts on ziftomenib, including four oral presentations, were…
Impact 4/10
Sep 30, 2026 Inst.
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP · ADD
2,751,191 shares ($29.5M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
2 drugs tracked · Drug pipeline →
Recent
Nov 13, 2026
Press release
Kura Oncology to Participate in Two Investor Conferences in November
SAN DIEGO, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the…
Nov 10, 2026
Earnings
Kura Oncology Reports Third Quarter 2026 Financial Results and Corporate Update
KOMZIFTI ® (ziftomenib) net product revenue grew 53% sequentially to $13.9 million; new patient starts increased 30% and total prescriptions grew 65%
Nov 10, 2026
Earnings result
KURA Q3 2026 Earnings: EPS $-0.78 (+7.0% vs est)
Nov 6, 2026
Press release
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company focused on precision…
Nov 4, 2026
Contract
Kura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026
Two oral presentations to feature first ziftomenib combination data with quizartinib in newly diagnosed and gilteritinib in relapsed/refractory…

SecBot reports

20 filings · 9 press releases · 7 bullish · 1 bearish · 1 mixed · 11 neutral
All KURA filing & press-release reports (29)